BOOK NOTICES


This is a new book covering the management and treatment of lung disease. The four authors are from the National Heart and Lung Institute, with contributions from Dr Rob Miller and Dr Norman Horne on AIDS and tuberculosis, respectively. The chapter headings cover obstructive airways diseases and respiratory failure, respiratory infections including opportunistic infections, AIDS and tuberculosis, lung cancer, pulmonary vascular disease, and drug-induced pulmonary disease, together with an initial chapter on general principles of drug treatment and a further chapter on symptom management. The chapters are focused on individual drugs and on the diseases and their management. The book has a pleasing format with several boxes in each chapter to highlight important points.

The style and layout of the book varies considerably between chapters. Those on opportunistic infection, tuberculosis, and cancer are clear, practical, and authoritative, giving details of the drugs available, followed by management strategies, and what to do when complications arise. The example, heparin is used for anticoagulation and antituberculous drugs or failure to respond to treatment for Pneumocystis carinii pneumonia. These are chapters that I will use (and have already used) for practical help when problems arise. They pull together areas which the non-specialist finds difficult to keep track of such as the role of chemotherapy in non-small cell lung cancer. The reader is given a clear picture of the state of the art. Some of the other chapters were less satisfactory since there seemed to be some confusion between what might be expected theoretically and what had been demonstrated in clinical practice. These chapters were well-organised and the writing sometimes had a slightly "off the cuff" feel to it, with repetition and, occasionally, contradictions. Some statements could be questioned – for example, administration of heparin for five days for a deep vein thrombosis, or the statement that patients with pure respiratory failure do not develop bicarbonate retention (surely this is a function of time of increased carbon dioxide levels). I was also concerned by an action plan for asthma that allows PEF to fall to 30% of normal before suggesting that medical attention should be sought.

There is a tendency to adopt a technique used by medical students which is to say that a certain treatment should be used – what the reader wants to know is how, when, and where it should be used and whether there is evidence that it is beneficial. Many conditions are not covered such as lung abscess, empyema, sarcoidosis, fibrosing alveolitis, alveolar haemorrhage, and many less common conditions. There is relatively little on bronchiectasis and, more surprisingly perhaps, no discussion of the role of nutrition or inhaled amiloride, steroids, or DECA in the management of cystic fibrosis.

There is a need for a book on therapeutics in respiratory disease and this book succeeds for some diseases. If the book as a whole is to fulfill this niche the style needs to be more uniform and the reader would be interested to know that most diseases and most aspects of treatment will be covered. There are many reviews on research in progress and, although an outline of drugs in the early stages of development is valuable, this must be distinguished from treatment that is of proven value. – AET

Respiratory Disease in Children: Diagnosis and Management G M Loughlin and H Ho (Pp 870; £112.00). Baltimore: Williams and Wilkins, 1994. 0 683 05190 3

This is a sizeable but interesting book of 870 pages which is a little different from other textbooks on the topic of respiratory disease in children. Sections include scientific foundations, diagnostic techniques, clinical assessment, and common and unusual respiratory disorders, with an innovation for books of this type in that a relatively small section is devoted to common problems such as noisy breathing, cough, haemoptysis, and chest pain. The majority of the contributors are from North America and it appears to have developed out of a paediatric pulmonology training programme; the foreword heralds the book as a product of second generation paediatric lung specialists. The style of individual chapters varies widely between standard reviews for example, on airways mechanics and respiratory control – to chapters which are more like review articles in medical journals – such as the chapter on the development of airways responsiveness and its relationship to asthma. There are some ambiguities between contributors – for example, in the origins of lung disease the genetic versus the acquired hypothesis for chronic obstructive lung disease in adult life is reviewed, whereas in the next chapter on prevention of lung disease the contributor care not to mention respiratory infection as the most likely early life cause of adult chronic obstructive lung disease.

Contributions on diagnostic tests are not very well integrated in the text. There is no mention of infant lung function testing which one would expect in a book of this size. The imaging chapter is particularly useful with many chest radiographs supported by secondary imaging investigations. A very useful section on the principles of treatment includes the statistical background to clinical trials and issues such as identification of correct sample size. The list of medical treatments and drugs used is North American in flavour and will require translation for the European and Australasian markets. There are useful sections on home care, nutritional management, and chest physiotherapy. Overall this is a very welcome addition to the growing number of paediatric pulmonology textbooks. I would certainly recommend it for those with a special interest in paediatric pulmonology and, bearing in mind the origins of the work, this is probably what the authors intended. With a price of £112 it is likely that this book will only find its way into the hands of those individuals who are planning to make a career in paediatric pulmonology or those responsible for training programmes. – PJH

BOOKS

Effects of ACE inhibition on sodium excretion in COPD

The limitations of angiotensin converting enzyme (ACE) inhibitors in promoting natriuresis in patients with cor pulmonale discussed by Dr A G Stewart and colleagues (October 1994;49:995–8) would not detract from the potential benefits of ACE blockade in retarding deterioration of left ventricular systolic function in COPD patients which is a result of mediation of cigarette smoking in the pathogenesis of chronic obstructive pulmonary disease (COPD) and coronary heart disease, respectively. We have recently reviewed left ventricular systolic dysfunction in COPD patients who have been treated with ACE inhibitors for left ventricular systolic failure in order to clarify issues raised in the paper. We should be more vigilant in documenting the association of COPD and left ventricular systolic dysfunction in patients with cor pulmonale because co-prescription of long term oxygen therapy for cor pulmonale and ACE inhibitors for left ventricular systolic failure could improve life expectancy, especially when associated with cessation of cigarette smoking.

O M J POLOBE
Department of Medicine for the Elderly, Tameside General Hospital, Ashton under Lyne, Lancashire OL6 9RW, UK

AUTHOR'S REPLY

The primary aim of our paper was to investigate the potential role of aldosterone as the cause of the sodium retention seen in patients with hypoxycaemic COPD. The ACE inhibitor perindopril was used as a tool to lower the raised aldosterone levels. Although chronic ACE inhibition did not improve sodium excretion, this does not detract from its potential use in the acute situation. We did not investigate the potential effects of ACE inhibition on well being, dyspnoea, exercise tolerance, or cardiac function in patients with COPD. These important parameters have been well studied in congestive cardiac failure. We look forward to seeing the results of similar studies in oedematous respiratory failure.

A G STEWART
on behalf of authors
Addenbrookes Hospital Cambridge CB2 2QF, UK


Effects of ACE inhibition on sodium excretion in COPD.

O M Jolobe

Thorax 1995 50: 430
doi: 10.1136/thx.50.4.430

Updated information and services can be found at:
http://thorax.bmj.com/content/50/4/430.1.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/